Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
Portfolio Pulse from
Eton Pharmaceuticals announced that the FDA has extended the PDUFA goal date for its New Drug Application for ET-400 to May 28, 2025.
February 06, 2025 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eton Pharmaceuticals' PDUFA goal date for ET-400 has been extended by the FDA to May 28, 2025, which may delay the potential market entry of the drug.
The extension of the PDUFA goal date suggests a delay in the approval process for ET-400, which could postpone its market entry and potential revenue generation. This is likely to have a negative short-term impact on Eton's stock price as investors may react to the delay.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100